Connect with us

Technology

KELYNIAM ACHIEVES RECORD REVENUE & PROFITABILITY FOR 2024

Published

on

CANTON, Conn., March 17, 2025 /PRNewswire/ — Kelyniam Global (OTC:KLYG), a manufacturer of custom cranial implants, has announced its financial results for the year ended December 31, 2024.

“Kelyniam had an exceptionally strong year in 2024,” stated Ross Bjella, Kelyniam’s CEO. “This marks the strongest performance in the company’s history both financially and operationally. Our success is attributed to our dedicated team of distributors and to Desiree Webb, Vice President of Operations and Business Development, who has developed a skilled manufacturing team that ensures the timely delivery of high-quality custom PEEK implants.”

Financial highlights for the year ended December 31, 2024, compared to the same period in 2023 include:

Total revenue: $3,328,382 compared to $2,672,357, an increase of 24.6%

Operating income: $277,037 compared to a loss of ($239,166), an improvement of $515,203

EBITDA: $322,824 compared to an EBITDA loss of $189,758, reflecting an earnings/cash contribution of $512,582

Events that significantly influenced the year included:

15 new hospitals purchased implants from Kelyniam in 2024Completion of an FDA audit late last year resulting in 5 minor observations, all of which have been addressedSponsorship of the Skull Base 360 wet lab at the University of Maryland, enhancing relationships with leading teaching institutions

The complete financials are available on the company’s website at www.Kelyniam.com.

“We look forward to building on the success of 2024 by strengthening our relationships with current partners, in-licensing products, and pursuing organic growth,” Bjella continued. “Kelyniam will significantly invest in sales and business development activities in 2025. The company is well-positioned to partner with foreign companies with cranial surgery products seeking a distribution partner or access to a U.S. FDA-approved manufacturing facility.”

Kelyniam Inc., specializes in the rapid production of custom prosthetics utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers.  The Company develops, manufactures, and distributes custom cranial and maxillo-facial implants for patients.  Kelyniam works directly with surgeons, health systems and payors to improve clinical and cost-of-care outcomes. Kelyniam’s web site address is www.Kelyniam.com.

As a cautionary note to investors, certain matters discussed in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; the Company’s ability to execute its service and product sales plans; changes in the status of ability to market products; and the risks described from time to time in the Company’s SEC reports.  

View original content:https://www.prnewswire.com/news-releases/kelyniam-achieves-record-revenue–profitability-for-2024-302402509.html

SOURCE Kelyniam Global Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

LG BEGINS PREORDERS FOR THE WORLD’S FIRST 5K2K OLED GAMING MONITOR – THE LG ULTRAGEAR GX9

Published

on

By

LG UltraGear GX9 (45GX950A-B) Delivers Unparalleled Visuals, Cutting-Edge Performance and Advanced Gaming Features

ENGLEWOOD CLIFFS, N.J., March 17, 2025 /PRNewswire/ — LG Electronics USA (LG) today announced preorder availability for its highly anticipated 45-inch LG UltraGear™ GX9 (45GX950A-B) — the world’s first 5K2K (5120×2160) OLED gaming monitor.1 Engineered for the most demanding gamers, this groundbreaking display sets a new standard for immersive visuals and ultra-fast refresh rates. The LG UltraGear GX9 retails for $1,999 and is available now for preorder through March 30, 2025 on LG.com and purchasable later at LG-authorized retailers.

The GX9 redefines gaming displays with its 45-inch OLED panel and 800R curvature, delivering a 5K2K Wide Ultra High Definition (WUHD) resolution for an unparalleled immersive experience. Dual-mode refresh rate technology allows gamers to choose between 5K2K at 165Hz or Wide Full HD (WFHD) at 330Hz, paired with an ultra-fast 0.03ms response time for ultimate speed and precision.

With VESA DisplayHDR™ True Black 400 certification and up to 98.5% DCI-P3 color spectrum coverage, the GX9 produces deep blacks and vibrant colors, ensuring stunning image quality. NVIDIA® G-SYNC® and AMD FreeSync™ Premium Pro compatibility eliminate screen tearing and stuttering, providing fluid gameplay in fast-paced environments.

The GX9 is designed to accommodate the latest gaming setups with DisplayPort 2.1, USB Type-C, and HDMI 2.1 connectivity. Additionally, the monitor features built-in speakers and DTS Headphone:X® support, delivering an immersive audio experience. In addition, advanced anti-glare technology minimizes screen reflections and glare, making it easier for gamers to see everything that’s happening on screen, even in brighter rooms.

The monitor seamlessly blends outstanding performance with a sleek, minimalist design. Its 4-sided Virtually Borderless display and slim bezels enhance immersion, while hexagonal lighting adds a modern touch. Designed for ergonomic comfort, the fully adjustable stand allows for tilt, swivel, and height adjustments, ensuring an optimal viewing experience. Additionally, the L-shaped stand contributes to a clean and streamlined desktop setup.

For more information on the LG UltraGear GX9 and LG’s full lineup of 2025 monitors, visit LG.com.

1Based on internal audit of published specifications in the OLED gaming monitor category as of March 2025.

About LG Electronics USA
LG Electronics USA Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics Inc., a smart life solutions company with annual global revenues of more than $60 billion. In the United States, LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems and vehicle components. LG is an 11-time ENERGY STAR® Partner of the Year. www.LG.com.

Media Contacts:

LG Electronics USA

LG Electronics USA 

Chris De Maria

Christin Rodriguez   

christopher.demaria@lge.com

christin.rodriguez@lge.com

LG-One

Amy Dalkoff

LGMSUS@LG-One.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lg-begins-preorders-for-the-worlds-first-5k2k-oled-gaming-monitor–the-lg-ultragear-gx9-302402693.html

SOURCE LG Electronics USA

Continue Reading

Technology

C.R. England Advances Industry Excellence with Lytx Video Safety Technologies

Published

on

By

The U.S.’s premier carrier chooses Lytx to help fulfill C.R. England’s “Safe & On Time, Every Time” commitment to its customers

SAN DIEGO, March 17, 2025 /PRNewswire/ — Lytx® Inc., the industry icon of video and safety-driven efficiency, today announced that C.R. England has selected Lytx to help protect the carrier’s 4,000 professional drivers operating its fleet of more than 3,500 tractor trucks.

The company, based in Salt Lake City, UT, will outfit its entire fleet with Lytx DriveCam® Event Recorders, which use Lytx’s proprietary machine vision and artificial intelligence technology (MV+AI)[1] to identify driving risks, including distracted driving, handheld cell phone use, lack of seat belt use, following too closely, and more.

“For years, we’ve admired C.R. England and the England family for their leadership in safety and their commitment to exceptional service,” said David Riordan, Executive Vice President at Lytx. “We are honored to have the opportunity to help protect C.R. England’s people, its equipment, and its century-long heritage and storied reputation.”

“Nothing we do is more important than making sure our team members and the public return home safely,” said Chad England, Chief Executive Officer of C.R. England, one of North America’s largest private, family-owned transportation and logistics companies. “It’s why we invest heavily in driver training and top-tier technology from innovative companies like Lytx.”

C.R. England selected Lytx after an extensive, three-month competitive evaluation against two other video safety providers. Success criteria included the performance and accuracy of the technology used to identify risks, as well as a demonstrated history of innovation.

“Our company is built on a core commitment to delivering excellence,” England said. “For us, excellence is not a one-and-done exercise. It’s a continuous pursuit to always operate at the leading edge with the best tools and technologies available. With its 27-year track record of high-velocity innovation, Lytx is the right choice to help us advance our ambitious safety goals.”

A pioneer in the transportation industry, C.R. England is a fourth-generation, family owned and operated carrier, founded in 1920 by Chester R. England. It was the first carrier in the U.S. to offer 72-hour cross-country, over-the-road freight service. Today, the company provides intermodal, dedicated, truckload, and logistics services in the U.S. and Mexico.

“As our business continues to grow, we needed a partner that could scale with us while enhancing our commitment to safety excellence,” said Colin England, Director of Accident Prevention at C.R. England. “Lytx’s dedication to customer success, combined with its significantly more advanced technology compared to our previous tools, made it the ideal choice for us.”

About C.R. England
C.R. England is a privately-owned, customer and employee-focused company that has been moving America’s freight safely since 1920. A pioneer in transportation, C.R. England provides asset-based dedicated, truckload, and intermodal solutions to solve a wide variety of customer needs. Large and small shippers rely on C.R. England as a strategic partner to haul their shipments safely and on time. C.R. England is committed to doing things the right way: supporting its drivers, investing in equipment, and continuing to provide innovative solutions to meet the demands of today’s shippers. With headquarters in Salt Lake City, Utah, and four company-sponsored driving schools throughout the nation, C.R. England is an industry leader in keeping America connected. For more information, visit www.CREngland.com.

About Lytx
Lytx is a global leader in video safety and video telematics. Our solutions harness the power of video to empower drivers and fleets to be safer and more efficient, productive, and profitable so they can thrive in today’s competitive environment. Through the Lytx Vision™ Platform, direct and reseller clients access our customizable services and programs spanning fleet safety, risk detection, fleet tracking, ELD compliance, preventative maintenance, and fuel management. Using the world’s largest driving database of its kind, along with proprietary machine vision and artificial intelligence technology, we help protect and connect thousands of fleets and 3.4 million drivers in more than 85 countries. For more information about Lytx, visit www.lytx.com, @lytx on X, LinkedIn, our Facebook page, or our YouTube channel.

[1] The MV+AI technology is a driver aid only. Drivers should never wait for a warning before taking measures to avoid an accident. The MV+AI distraction detection and alerting technology does not collect, store or use any biometric identifiers or biometric information (e.g., scans of facial geometry) to detect distracted driving behaviors. See https://www.lytx.com/driver-information.

Contact:
Jason Andersen
corpcomm@lytx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cr-england-advances-industry-excellence-with-lytx-video-safety-technologies-302402627.html

SOURCE Lytx, Inc.

Continue Reading

Technology

VAS101, a Novel Curcumin Transdermal Formulation, Reverses Some Clinical Hallmarks of Aging

Published

on

By

SUMMIT, N.J., March 17, 2025 /PRNewswire/ — In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel curcumin transdermal formulation developed by Vascarta Inc. (Summit, NJ, USA), when administered topically twice weekly i) restored physical and cognitive function in aged mice as well as improving markers of frailty; ii) reduced age associated inflammation (inflammaging) markers in multiple organs; iii) initiated tissue remodeling in aging hearts; and iv) lowered interleukin 11 (IL-11) expression in the kidney. The inhibition of IL-11 via a biologic was recently shown to increase the life span of mice [see Widjaja, A.A., et al, Inhibition of IL-11 signaling extends mammalian healthspan and lifespan. Nature, 632(8023), pp.157-165]. The present study also demonstrated that topically applied VAS101 can accelerate restoration of vascular health as reflected in normalizing blood pressure in an endothelial dysfunction model.

Vascular health is generally regarded as key to general health with endothelial dysfunction responsible for many age-related system failures. VAS101 provides a unique mechanism for delivery of curcumin to the endothelial lining of those blood vessels that are essential for vascular health.  VAS101 was shown in prior studies to effectively load red blood cells with curcumin (Curc-RBCs), improving both their ex vivo stability and extending circulation time in a surrogate animal model. Curc-RBCs were also shown to cross the blood brain barrier and deactivate activated mast cells and microglia and, in turn, limit chronic pain and neuro-inflammation. Curc-RBCs are not targeted by immune cells nor, like many intravenously- administered drugs and nanoparticle delivery vehicles, subjected to hepatic first-pass effect, thus allowing for full and sustained systemic delivery of the active ingredient.

Unlike oral curcumin, which is poorly absorbed, rapidly cleared and otherwise entangled with albumin and other circulating proteins, VAS101, through its subsequent enrichment of Curc-RBCs, uniquely reaches the endothelial layer of smaller and narrower blood vessels that are most critical for organ and tissue health and function.

The many positive effects of VAS101 are at least in part attributable to the known nitric oxide (NO) enhancing capability of curcumin. Curcumin delivery to small diameter blood vessels is an optimal strategy for improving vascular function by enhancing local levels of NO in the endothelium.

Joel Friedman, M.D., Ph.D., professor of microbiology & immunology and of medicine at Albert Einstein College of Medicine and Vascarta Scientific Founder and Head, Scientific Advisory Board, stated, “Realizing curcumin’s well-documented effects on general health have been limited by the ability to achieve sustained, therapeutic concentrations in target tissues. What has been needed is a safe, cost-effective, and easy to use formulation that can be deployed over an extended period of time that targets the appropriate tissues. Transdermal VAS101 (Vasceptor®) may fill this gap and provide a novel way to restore some key elements of vascular health and slow and possibly reverse the aging process.” [Dr. Friedman is a co-author on the GeroScience paper and the inventor of VAS-101 which is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA)].

Senior author Derek Huffman, Ph.D., professor of molecular pharmacology and of medicine and Co-Director of the Nathan Shock Center at Einstein, remarked, “We observed that a short intervention with transdermal VAS101 resulted in a number of favorable effects on health in mice.  This included improved aspects of health span such as exercise capacity and reduced frailty. Based upon these data, VAS101 may have potential to be a safe and effective therapeutic to treat aging.”

Dr. Richard Prince, Vascarta Chairman, CEO and President, said, “As part of our commitment to making the health benefits of curcumin widely available, we are initiating human studies and will seek FDA approval of transdermal Vasceptor® in a range of conditions characterized by pain and inflammation.”

About Vascarta

Vascarta is a clinical stage pharmaceutical company exploring efficient transdermal delivery of pharmaceuticals to address several conditions with an initial focus on sickle cell disease and osteoarthritis. For those interested in learning more about Vascarta’s clinical programs, contact Chairman, CEO & President Dr. Richard Prince at rprince@vascarta.com.  Media requests should be directed to David Hymson at dhymson@vascarta.com.

Publication Authors & Affiliations

Kai Mao1,2,4, Ruixuan Wang1,4, Kateryna Karpoff1,4, Daniel Kerr5, Probal Banerjee6, Joel M. Friedman2,3,7 and Derek M. Huffman1,2,4,†

Departments of 1Molecular Pharmacology, 2Medicine, 3Microbiology & Immunology, and the 4Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA
5The Center for Developmental Neuroscience and 6Department of Chemistry, CUNY College of Staten Island, NY 10314, USA

7Vascarta Inc, Summit, NJ, 07901, USA 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vas101-a-novel-curcumin-transdermal-formulation-reverses-some-clinical-hallmarks-of-aging-302403204.html

SOURCE Vascarta Inc

Continue Reading

Trending